TMCnet News
Dimension Therapeutics Elects Dr. Alan B. Colowick to Its Board of DirectorsDimension Therapeutics, Inc. ("Dimension" or the "Company"), a leading rare disease company advancing novel, liver-directed treatments for diverse genetic disorders, today announced the election of Alan B. Colowick, M.D., M.P.H., Executive Vice President of Celgene Corporation, to Dimension's Board of Directors (the "Board"). Dr. Colowick brings strong operational expertise and more than 15 years of experience in biopharmaceutical development. His election to the company's Board is effective immediately. "Alan has a successful and highly regarded career in the life sciences, and we are pleased to welcome him to Dimension's Board," said Annalisa Jenkins, MBBS, MRCP, Chief Executive Officer of Dimension. "His track record in advancing products into the market and successfully commercializing them will be vital as we continue to progress our lead programs for rare, genetic diseases associated with the liver, including our wholly owned program in hemophilia B, which is anticipated to enter the clinic this year." "Alan has built and managed highly regarded clinical teams capable of supporting multiple, simultaneous clinical trials on a global basis," stated Ben Auspitz, Partner, Fidelity Biosciences, and Chairman of Dimension's Board. "We expect we will benefit greatly from his insights and unique perspective addressing patient populations with substantial unmet needs." >
About Dimension Therapeutics Dimension Therapeutics, Inc. is a rare disease company focused on discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver and based on the most advanced adeno-associated virus (AAV) delivery technology. The company is advancing multiple programs toward clinical development, including: programs addressing unmet needs for patients suffering from OTC deficiency and GSDIa; a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in hemophilia B, which is expected to enter clinical testing in 2015. Dimension has preferred access to multiple AAV vectors from REGENXBIO. The Dimension team and senior advisors include biotech industry veterans and renowned thought leaders in gene therapy and rare diseases. For more information please visit www.dimensiontx.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20150922005292/en/ |